Online citations, reference lists, and bibliographies.
← Back to Search

Do We Need A Revised Staging System For Malignant Pleural Mesothelioma? Analysis Of The IASLC Database.

V. Rusch, D. Giroux
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
INTRODUCTION A number of staging systems have been proposed for malignant pleural mesothelioma (MPM) in the past, but few have utilized a TNM (tumor, node, metastasis) system. The International Association for the Study of Lung Cancer (IASLC) and the International Mesothelioma Interest Group (IMIG) previously developed a TNM-staging system which has been accepted by the International Union Against Cancer (UICC) and the American Joint Commission on Cancer (AJCC). The present study examines this staging system by analysing the updated IASLC database for patients with MPM. METHODS De-identified data from participating centres dated from 1995 to 2009 were submitted to the IASLC Statistical Center. Surgical procedures included those with a curative or palliative intent. Survival was measured from the date of pathologic diagnosis to the most recent contact or death. Endpoints included overall survival and analysis of potential prognostic factors. RESULTS Data was available for 3,101 patients from 15 centers, mostly from North America and Europe. After a median follow-up of 15 months, a number of clinicopathological and treatment-related prognostic factors were found to significantly influence overall survival. These included overall tumor stage based on the proposed TNM staging system, T category, N category, tumor histology, gender, age, and type of operation. CONCLUSIONS The IASLC database represents the largest, multicenter and international database on MPM to date. Analyses demonstrate that the proposed TNM staging system effectively distinguishes the T and N categories, but also highlight areas for potential revision in the future.
This paper references
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1510/icvts.2010.262972
Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma--institutional review and current update.
C. Cao (2011)
10.1016/j.ejcts.2008.03.003
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
C. Aigner (2008)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
10.1016/J.JTCVS.2006.06.044
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2007)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1097/JTO.0b013e31812f3c1a
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
P. Goldstraw (2007)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.5761/ATCS.OA.10.01572
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
10.1016/S1470-2045(11)70307-2
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
10.1016/S1077-9108(08)79041-8
Malignant Pleural Mesothelioma: Surgical Management in 285 Patients
P. Bejarano (2009)
10.1016/S0169-5002(07)70198-8
122 Risk factors for major complications after extrapleural pneumonectomy
M. Perrot (2006)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1016/j.ejcts.2009.07.032
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
H. Luckraz (2010)
10.1016/j.ejcts.2009.12.039
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
A. Nakas (2010)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
10.1016/J.EJCTS.2007.01.064
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Do we need a revised staging system for malignant pleural mesothelioma ? Analysis of the IASLC database
H Luckraz
10.1016/j.ejcts.2008.06.010
Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
A. Nakas (2008)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1080/08858198809527918
[International Union Against Cancer].
C. Sherman (1952)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1016/j.ejcts.2010.12.024
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
D. Sugarbaker (2011)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1093/jjco/hyn145
A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.
T. Yamanaka (2009)
10.1118/1.3525836
Computerized segmentation and measurement of malignant pleural mesothelioma.
W. Sensakovic (2011)
10.1097/JTO.0b013e31816fca1b
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1016/j.hlc.2010.11.045
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2011)
10.1016/j.athoracsur.2008.01.088
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
T. Mineo (2008)
10.1016/j.jtcvs.2008.12.045
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
10.1016/j.ejrad.2009.02.002
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
G. Ak (2010)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1097/JTO.0b013e3181ae25bf
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
10.1002/cncr.24886
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases
W. Richards (2010)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)



This paper is referenced by
10.1183/09031936.00207213
Multimodal management of malignant pleural mesothelioma: where are we today?
P. V. Van Schil (2014)
10.21037/jtd.2017.10.09
Clinical diagnosis of malignant pleural mesothelioma.
A. Bianco (2018)
10.1080/2331205X.2017.1421007
Preoperative evaluation of six-minute walk test in patients with malignant pleural mesothelioma
M. Nagaya (2017)
10.1007/s00268-017-4264-4
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma
W. Vigneswaran (2017)
10.1016/j.jtcvs.2014.01.007
WITHDRAWN: Is there life after the Mesothelioma and Radical Surgery trial? Does extrapleural pneumonectomy still have a role in the management of pleural mesothelioma? A 13-year, single-center experience.
S. Qadri (2014)
10.1016/J.EJRAD.2019.04.003
Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI.
D. Murphy (2019)
10.1007/978-3-319-28761-4_21
Modern Surgical Techniques in Malignant Pleural Mesothelioma
Y. Kahya (2016)
10.1016/j.lungcan.2020.06.034
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
J. Remon (2020)
10.1177/2373997515595219
Extrapleural Pneumonectomy A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma
S. Qadri (2015)
10.1002/cncy.21928
A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma
Y. Kinoshita (2018)
10.1016/j.athoracsur.2016.08.063
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
W. Vigneswaran (2017)
10.1055/s-0034-1365025
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
Características clínicas, espirométricas y radiológicas de los trabajadores expuestos al amianto en el área sanitaria de Ferrol: experiencia de una consulta monográfica de vigilancia post-ocupacional : Febrero 2002-Febrero 2009
Diego Roza (2015)
10.1093/ejcts/ezv403
The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication.
A. Sharkey (2016)
10.21037/tlcr.2018.07.05
The eighth TNM classification for malignant pleural mesothelioma.
L. Berzenji (2018)
10.1016/j.jtho.2016.04.027
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
10.1183/13993003.01428-2016
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
10.1007/978-3-030-16884-1_10
Measuring Malignant Pleural Mesothelioma
A. Nowak (2019)
10.1093/ejcts/ezt664
Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
A. Nakas (2014)
10.3322/caac.21498
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
D. Mahvi (2018)
10.1017/9781316402009.004
Multi-modality Imaging of Pleural and Peritoneal Disease
J. Cunningham (2018)
10.1007/978-1-4939-2374-8_3
Clinical and Radiologic Features
A. Roden (2015)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.1016/j.lungcan.2017.09.015
Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
O. Abdel-Rahman (2017)
10.21037/shc.2018.07.01
Advances in mesothelioma imaging and implications for surgical management
K. Blyth (2018)
10.1038/bjc.2014.312
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
G. Ceresoli (2014)
10.1093/ejcts/ezv422
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
Diana Y. Kircheva (2016)
10.3978/j.issn.2072-1439.2013.07.40
Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
M. A. Bedirhan (2013)
10.5858/arpa.2017-0245-RA
Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.
A. Nicholson (2018)
10.1136/bmjopen-2016-013324
Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study
S. Tsim (2016)
10.21037/atm.2017.03.97
Overview of treatment related complications in malignant pleural mesothelioma.
D. Murphy (2017)
10.21037/tlcr-19-488
Does size matter? -a population-based analysis of malignant pleural mesothelioma.
J. He (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar